Cargando…

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature

Salivary gland carcinomas metastasize to distant organs in 20% of salivary gland malignancies. Applying immunohistochemistry (IHC) measures, salivary gland tumors showed a wide range of oncogene markers expression, including the human epidermoid receptor 2 (Her2/neu), which could be targeted with mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Firwana, Belal, Atassi, Bassel, Hasan, Rim, Hasan, Nour, Sukari, Ammar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697425/ https://www.ncbi.nlm.nih.gov/pubmed/23826550 http://dx.doi.org/10.4103/2231-0770.102282

Ejemplares similares

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
por: Corrêa, Tatiana Strava, et al.
Publicado: (2018)

Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer
por: Wang, Fuzhang, et al.
Publicado: (2022)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
por: Sbitti, Yassir, et al.
Publicado: (2011)

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2016)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Evaluation of HER2/neu expression in different types of salivary gland tumors: a systematic review and meta-analysis
por: Javaheripour, Aylar, et al.
Publicado: (2022)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar, Ibrahim, et al.
Publicado: (2021)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Successful Treatment of HER2-neu–positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support
por: Smith, Julie
Publicado: (2012)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer
por: Basade, M., et al.
Publicado: (2018)

Nephrotic syndrome after treatment of Crohn's disease with mesalamine: Case report and literature review
por: Firwana, Belal M., et al.
Publicado: (2012)

HER2‐positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab‐based chemotherapy: A case report
por: Longo, Raffaele, et al.
Publicado: (2020)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Metastatic Malignant Paraganglioma: A Case Report and Review of Literature
por: Prades, Carlo Angelo, et al.
Publicado: (2017)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2014)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
por: Esteva, Francisco J, et al.
Publicado: (2005)

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
por: Petricevic, Branka, et al.
Publicado: (2013)

Undergraduate medical students’ perceptions, attitudes, and competencies in evidence-based medicine (EBM), and their understanding of EBM reality in Syria
por: Alahdab, Fares, et al.
Publicado: (2012)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma
por: Pachmann, Katharina, et al.
Publicado: (2011)

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab
por: Königsberg, Robert, et al.
Publicado: (2014)

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature
por: Goodman, Oscar B, et al.
Publicado: (2009)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

Novel Meibomian Gland and Tarsal Conjunctival Changes Associated with Trastuzumab, Pertuzumab, and Anastrozole Treatment for Metastatic HER2 Positive Breast Cancer: A Case Report and Literature Review
por: Barcsay-Veres, Amarilla, et al.
Publicado: (2022)

Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
por: Gunia, Sommer R., et al.
Publicado: (2012)

Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-neuT) in Mice with Transplanted Salivary Gland Carcinoma Cells
por: Focaccetti, Chiara, et al.
Publicado: (2020)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review
por: Firwana, Belal M., et al.
Publicado: (2011)

Cancer Care at Times of Crisis and War: The Syrian Example
por: Sahloul, Eman, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ooh94hkido4uoqk62flm2ufj09